ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Author(s):

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

Video content above is prompted by the following questions:

Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)
1. What was the objective of this study?
2. How was this study designed/what methodology was used?
3. What results were presented?
  1. N=155
  2. Median follow-up: 21.78 months
  3. PFS
  4. ORR
  5. Median duration of response
  6. OS
  7. Safety
Please provide your key takeaways from this study.How might these findings impact the management of patients with RRMM?
Belantamab mafodotin was previously withdrawn from the US market for RRMM following results from the phase 3 DREAMM-3 trial (NCT04162210) which did not meet its primary endpoint of progression-free survival (PFS). How do the results of the DREAMM-8 trial shed light on potential advantages of BPd in patients with RRMM?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.